AUS
NZ
UK
CA
USA
IND
_09_15_2025_06_09_10_957293.png)
Highlights:
- Avricore Health Inc. Reports a Net Loss of CAD 0.179 Million for Q3 2024
- Sales Growth in Q3 and Nine-Month Period Shows Strong Performance
- Stock Performance Shows a Year-to-Date Decline of 67.65%
Avricore Health Inc. (TSE:AVCR), a leading IT services and consulting company in the healthcare sector, recently released its financial results for the third quarter and nine months ended September 30, 2024. Despite reporting a loss for Q3, Avricore has shown significant progress in terms of sales growth and overall business development. This article delves into the company’s earnings report, recent performance, and stock activity.
Earnings Results for Q3 and Nine-Month Period
For the third quarter of 2024, Avricore Health Inc. reported sales of CAD 1.2 million, which represents an increase compared to CAD 0.95 million in the same period last year. This growth in sales highlights the company’s expanding footprint in the healthcare IT services sector. However, despite the rise in sales, Avricore still posted a net loss of CAD 0.179 million for the quarter, an improvement over the CAD 0.285 million loss incurred during Q3 2023.
For the nine months ended September 30, 2024, the company reported sales of CAD 3.36 million, compared to CAD 2.13 million for the same period in 2023, reflecting a notable increase in revenue. In a significant positive development, Avricore reported a net income of CAD 0.043 million for the nine months, contrasting with a net loss of CAD 0.76 million during the same period last year. This marks an encouraging turnaround for the company as it moves toward profitability.
Business Growth and Strategic Developments
Avricore Health Inc. continues to advance its position in the healthcare technology space, providing IT solutions that aim to improve healthcare delivery through digital innovation. The company’s growth in sales reflects increasing demand for its services, which includes developing and integrating technologies that optimize healthcare practices.
Despite the challenges presented by the healthcare industry’s evolving landscape, Avricore has managed to position itself as a key player in the sector, making strides toward long-term profitability. The increase in sales, coupled with the reduction in net losses, reflects the company’s successful efforts in expanding its customer base and enhancing its service offerings.
Stock Performance and Market Activity
As of November 28, 2024, Avricore Health Inc. (AVCR) closed at CAD 0.0550, with no change for the day. While the stock has experienced no short-term gains, its long-term performance remains under pressure with a year-to-date decline of 67.65%. Despite the challenges in the stock price, the company’s performance in terms of sales growth and positive net income for the nine-month period offers investors hope for a potential recovery.
The market’s cautious approach to Avricore’s stock might be due to the broader market volatility, but the underlying sales growth and operational improvements may signal a brighter future for the company. Investors are likely waiting for continued positive financial results and further developments in the company’s business strategy to drive confidence in the stock’s long-term potential.
Avricore Health's Future Outlook
Looking forward, Avricore Health Inc. remains focused on expanding its healthcare IT services and capitalizing on opportunities in the growing healthcare technology market. While the company’s stock has struggled this year, its positive revenue growth and shift toward profitability suggest that Avricore is on a path to recovery.
